FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of ...

NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial ...

NeoGenomics has seen a strong start to the year. The Fort Myers-based cancer testing and research lab reported revenue growth of 8% in the first quarter over the year. Revenue rose from roughly $156.2 ...

FORT MYERS, FL / ACCESSWIRE / December 28, 2023 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading oncology testing services company, today announced that NeoGenomics Laboratories, Inc., a ...

Fort Myers-based cancer testing and research lab NeoGenomics saw its revenue grow by 12% over the year in the second quarter. Meanwhile, the company narrowed its losses by 23%. Revenue from clinical ...

NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform. Read why ...

FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will attend the Piper Sandler 36 th Annual Healthcare Conference. Members of the ...

Analyst Puneet Souda from Leerink Partners maintained a Buy rating on NeoGenomics (NEO – Research Report) and keeping the price target at $30.00. Puneet Souda has given his Buy rating due to a ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months. The table below offers a condensed view of ...